The proposed cancer cells targeted by ADT are incapable of Arg de novo synthesis mainly due to deficiency in argininosuccinate synthetase (ASS), the rate-limiting enzyme of citrulline (Cit) to Arg conversion [3, 7, 8]. Here, ASS1 is linked to cancer.